498 related articles for article (PubMed ID: 35869354)
1. A Narrative Review of Irritable Bowel Syndrome with Diarrhea: A Primer for Primary Care Providers.
Moshiree B; Heidelbaugh JJ; Sayuk GS
Adv Ther; 2022 Sep; 39(9):4003-4020. PubMed ID: 35869354
[TBL] [Abstract][Full Text] [Related]
2. Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea.
Brenner DM; Sayuk GS
Adv Ther; 2020 Jan; 37(1):83-96. PubMed ID: 31707713
[TBL] [Abstract][Full Text] [Related]
3. Journal of Clinical Gastroenterology Lectureship Dubai 2022 : Management of Irritable Bowel Syndrome With Diarrhea.
Marasco G; Cremon C; Barbaro MR; Stanghellini V; Barbara G
J Clin Gastroenterol; 2024 Mar; 58(3):221-231. PubMed ID: 38227850
[TBL] [Abstract][Full Text] [Related]
4. Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.
Rivkin A; Rybalov S
Pharmacotherapy; 2016 Mar; 36(3):300-16. PubMed ID: 26971716
[TBL] [Abstract][Full Text] [Related]
5. Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?
Cash BD; Lacy BE; Rao T; Earnest DL
Expert Opin Pharmacother; 2016; 17(3):311-22. PubMed ID: 26559529
[TBL] [Abstract][Full Text] [Related]
6. Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome.
Kane JS; Ford AC
Expert Rev Gastroenterol Hepatol; 2016; 10(4):431-42. PubMed ID: 26753693
[TBL] [Abstract][Full Text] [Related]
7. Management of irritable bowel syndrome with diarrhea: focus on eluxadoline.
Jones J; Lembo A; Heidelbaugh J; Kuritzky L; Lacy B
Curr Med Res Opin; 2021 Apr; 37(4):567-578. PubMed ID: 33566707
[TBL] [Abstract][Full Text] [Related]
8. Update on Eluxadoline for the Treatment of Irritable Bowel Syndrome with Diarrhea: Patient Selection and Perspectives.
Liu R; Staller K
Drug Des Devel Ther; 2020; 14():1391-1400. PubMed ID: 32308371
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in pharmacological treatment of irritable bowel syndrome.
Lazaraki G; Chatzimavroudis G; Katsinelos P
World J Gastroenterol; 2014 Jul; 20(27):8867-85. PubMed ID: 25083060
[TBL] [Abstract][Full Text] [Related]
10. Evidence-based management of irritable bowel syndrome with diarrhea.
Pimentel M
Am J Manag Care; 2018 Jan; 24(3 Suppl):S35-S46. PubMed ID: 29372991
[TBL] [Abstract][Full Text] [Related]
11. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
Dove LS; Lembo A; Randall CW; Fogel R; Andrae D; Davenport JM; McIntyre G; Almenoff JS; Covington PS
Gastroenterology; 2013 Aug; 145(2):329-38.e1. PubMed ID: 23583433
[TBL] [Abstract][Full Text] [Related]
12. Diarrhea-predominant irritable bowel syndrome: Diagnosis, etiology, and new treatment considerations.
Lacy BE; Moreau JC
J Am Assoc Nurse Pract; 2016 Jul; 28(7):393-404. PubMed ID: 27436200
[TBL] [Abstract][Full Text] [Related]
13. Treating Chronic Abdominal Pain in Patients with Chronic Abdominal Pain and/or Irritable Bowel Syndrome.
Stemboroski L; Schey R
Gastroenterol Clin North Am; 2020 Sep; 49(3):607-621. PubMed ID: 32718573
[TBL] [Abstract][Full Text] [Related]
14. Emerging treatments in neurogastroenterology: eluxadoline - a new therapeutic option for diarrhea-predominant IBS.
Lacy BE
Neurogastroenterol Motil; 2016 Jan; 28(1):26-35. PubMed ID: 26690872
[TBL] [Abstract][Full Text] [Related]
15. Episodic nature of symptoms in irritable bowel syndrome.
Palsson OS; Baggish J; Whitehead WE
Am J Gastroenterol; 2014 Sep; 109(9):1450-60. PubMed ID: 24980882
[TBL] [Abstract][Full Text] [Related]
16. Development of the Diary for Irritable Bowel Syndrome Symptoms to Assess Treatment Benefit in Clinical Trials: Foundational Qualitative Research.
Fehnel SE; Ervin CM; Carson RT; Rigoni G; Lackner JM; Coons SJ;
Value Health; 2017 Apr; 20(4):618-626. PubMed ID: 28408004
[TBL] [Abstract][Full Text] [Related]
17. Review Article: Current and future treatment approaches for IBS with diarrhoea (IBS-D) and IBS mixed pattern (IBS-M).
Nee J; Lembo A
Aliment Pharmacol Ther; 2021 Dec; 54 Suppl 1():S63-S74. PubMed ID: 34927757
[TBL] [Abstract][Full Text] [Related]
18. Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome.
Nee J; Zakari M; Lembo AJ
Expert Opin Pharmacother; 2015; 16(18):2781-92. PubMed ID: 26558923
[TBL] [Abstract][Full Text] [Related]
19. Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility.
Savarino E; Zingone F; Barberio B; Marasco G; Akyuz F; Akpinar H; Barboi O; Bodini G; Bor S; Chiarioni G; Cristian G; Corsetti M; Di Sabatino A; Dimitriu AM; Drug V; Dumitrascu DL; Ford AC; Hauser G; Nakov R; Patel N; Pohl D; Sfarti C; Serra J; Simrén M; Suciu A; Tack J; Toruner M; Walters J; Cremon C; Barbara G
United European Gastroenterol J; 2022 Jul; 10(6):556-584. PubMed ID: 35695704
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis.
Black CJ; Burr NE; Camilleri M; Earnest DL; Quigley EM; Moayyedi P; Houghton LA; Ford AC
Gut; 2020 Jan; 69(1):74-82. PubMed ID: 30996042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
